Funding: W.C. is supported by a postgraduate scholarship from the National Health and Medical Research Council of Australia and a support grant from GlaxoSmithKline Australia. A.J.T. is supported by the National Health and Medical Research Council Program Grant and the National Heart Foundation Grant, Melbourne, Australia.
Principles, current status and clinical implications of ischaemic heart disease assessment by cardiac magnetic resonance imaging
Article first published online: 26 JAN 2012
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 42, Issue 1, pages 7–17, January 2012
How to Cite
Chan, W., Ellims, A. H., Duffy, S. J., Kaye, D. M. and Taylor, A. J. (2012), Principles, current status and clinical implications of ischaemic heart disease assessment by cardiac magnetic resonance imaging. Internal Medicine Journal, 42: 7–17. doi: 10.1111/j.1445-5994.2011.02606.x
Conflict of interest: None.
- Issue published online: 26 JAN 2012
- Article first published online: 26 JAN 2012
- Accepted manuscript online: 14 OCT 2011 09:14AM EST
- Received 25 July 2011; accepted 20 September 2011.
- cardiac magnetic resonance imaging;
- myocardial oedema;
- myocardial infarction;
- microvascular obstruction
Cardiac magnetic resonance imaging (CMR) has matured into a robust, accurate and highly reproducible imaging modality for the assessment of cardiac function and ischaemic heart disease. The unique physical properties of CMR permit depiction of pathology-specific tissue contrast based on differences in tissue composition, such as myocardial oedema, necrosis and fibrosis. This can be imaged at high spatial resolution allowing characterisation of the acuity of an ischaemic event, the presence and extent of myocardial ischaemia, necrosis and viability. Prognostically important information obtained from CMR evaluation of ischaemic heart disease, such as left ventricular ejection fraction, infarct size and transmurality, infarct location and the presence of intraventricular mechanical dyssynchrony may be used to guide coronary revascularisation, device and medical therapies.